Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Quinidine is a class I antiarrhythmic drug and a stereoisomer of quinine, originally derived from the bark of the cinchona tree. It is known for its antiarrhythmic effects on the heart by interacting with electrophysiology mechanisms that cause arrhythmias, modifying abnormalities in impulse initiation and conduction. Quinidine depresses normal automaticity in cardiac fibers, blocks various ion channels, and has antimalarial properties.
Used in Pharmaceutical Industry:
Quinidine is used as an antiarrhythmic agent for the treatment of atrial fibrillation and ventricular arrhythmias. It helps in modifying the abnormalities in impulse initiation and conduction, which are responsible for arrhythmias.
Used in Antimalarial Applications:
Quinidine is used as an antimalarial agent for the prevention and treatment of malaria. It is a dextrorotatory stereoisomer of quinine, which is effective against the Plasmodium parasite responsible for causing malaria.
Used in Cardiology:
Quinidine is used as a class IA antiarrhythmic agent in cardiology for the prevention of certain cardiac arrhythmias. It interacts with various ion channels, including the voltage-gated sodium (Nav) channel Nav1.5, and helps in decreasing the amplitude and duration of action potentials in isolated canine ventricular myocytes.
Used in Cinchona Bark:
Quinidine occurs naturally in cinchona bark at about 0.25-0.3% concentration. It is also found in cuprea bark and quinine sulfate mother liquor. It is formed by the isomerization of quinine and is used for its antiarrhythmic and antimalarial properties.

56-54-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 56-54-2 Structure
  • Basic information

    1. Product Name: Quinidine
    2. Synonyms: (8R,9S)-6'-Methoxycinchonan-9-ol;(8r,9s)-quinidine;(95)-cinchonan-9-0;(9s)-6’-methoxycinchonan-9-ol;(9S)-6'-Methoxycinchonan-9-ol;2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-;6-Methoxy-alpha-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol;6'-Methoxycinchonan-9-ol
    3. CAS NO:56-54-2
    4. Molecular Formula: C20H24N2O2
    5. Molecular Weight: 324.42
    6. EINECS: 200-279-0
    7. Product Categories: chiral;Alkaloids;Alkoxyquinolines;Biochemistry;for Resolution of Acids;Optical Resolution;Quinoline Alkaloids;Quinolines;Synthetic Organic Chemistry;Intermediates & Fine Chemicals;Pharmaceuticals;Cinchona AlkaloidsMonovalent Ion Channels;Chiral Catalysts, Ligands, and Reagents;Other Sodium Channel Modulators;Privileged Ligands and Complexes;Sodium Channel Modulators;Chiral Reagents;Heterocycles;DURAQUIN
    8. Mol File: 56-54-2.mol
  • Chemical Properties

    1. Melting Point: 168-172 °C(lit.)
    2. Boiling Point: 462.75°C (rough estimate)
    3. Flash Point: 253.7 °C
    4. Appearance: White to off-white/Powder
    5. Density: 1.1294 (rough estimate)
    6. Vapor Pressure: 0mmHg at 25°C
    7. Refractive Index: 1.5700 (estimate)
    8. Storage Temp.: Store at -20°C
    9. Solubility: insoluble in H2O; ≥10.32 mg/mL in EtOH with ultrasonic; ≥11.95 mg/mL in DMSO
    10. PKA: 5.4, 10.0(at 20℃)
    11. Water Solubility: 0.05 g/100 mL (20 ºC)
    12. Sensitive: Light Sensitive
    13. Stability: Stable. Incompatible with strong oxidizing agents.
    14. Merck: 14,8060
    15. BRN: 91866
    16. CAS DataBase Reference: Quinidine(CAS DataBase Reference)
    17. NIST Chemistry Reference: Quinidine(56-54-2)
    18. EPA Substance Registry System: Quinidine(56-54-2)
  • Safety Data

    1. Hazard Codes: Xn
    2. Statements: 22-20/21/22
    3. Safety Statements: 36-22
    4. RIDADR: UN 2811 6.1/PG 3
    5. WGK Germany: 3
    6. RTECS: VA4725000
    7. F: 8
    8. TSCA: Yes
    9. HazardClass: 6.1(b)
    10. PackingGroup: III
    11. Hazardous Substances Data: 56-54-2(Hazardous Substances Data)

56-54-2 Usage

History

In 1820, the French chemists Pierre Pelletier and Joseph Caventou extracted some alkaloids from the cinchona bark, including quinine and quinidine. Subsequently, quinine was demonstrated to play a very important role in the treatment of malaria after a number of scientific researches. Quinidine is the dextroisomer of quinine and has the similar pharmacological properties as quinine, but quinidine’s effects are five to ten times stronger on the heart than quinine.

Indications

Quinidine acts as a class I antiarrhythmic agent (Ia) in the heart. It was clinically applicable to the treatment of recurrent, documented, life-threatening ventricular arrhythmias .

Biological Functions

Quinidine is an alkaloid obtained from various species of Cinchona or its hybrids, from Remijia pedunculata, or from quinine. Quinidine is the dextrorotatory isomer of quinine.Quinidine (Quinidex) was one of the first clinically used antiarrhythmic agents. Because of the high incidence of ventricular proarrhythmia associated with its use and numerous other equally efficacious agents, quinidine is now used sparingly. Quinidine shares all of the pharmacological properties of quinine, including antimalarial, antipyretic, oxytocic, and skeletal muscle relaxant actions.

Air & Water Reactions

Insoluble in water.

Hazard

Poison.

Health Hazard

Quinidine is more potent than quinine in itsaction on the cardiovascular system. Overdosesmay cause lowering of blood pressure.Gastric effects are lower than quinine. Toxicityis lower relative to quinine; subcutaneouslethal dose in mice is 400 mg/kg against200 mg/kg for quinine.

Fire Hazard

Flash point data for Quinidine are not available. Quinidine is probably combustible.

Biochem/physiol Actions

Class IA antiarrhythmic; potassium channel blocker.

Pharmacology

Quinidine exhibits all of the pharmacological properties of quinine, including antimalarial, fever-reducing, and other properties. Quinidine is used in various forms of arrhythmia for preventing tachycardia and atrial fibrillation, and particularly for preventing ciliary fibrillation, paroxysmal supraventricular tachycardia, extrasystole, and ventricular tachycardia. However, it is a toxic drug and is used relatively rarely. It is also prescribed under the name cardioquin, duraquin, quinidex, and others.

Clinical Use

Primary indications for the use of quinidine include (1) abolition of premature complexes that have an atrial, A-V junctional, or ventricular origin; (2) restoration of normal sinus rhythm in atrial flutter and atrial fibrillation after controlling the ventricular rate with digitalis; (3) maintenance of normal sinus rhythm after electrical conversion of atrial arrhythmias; (4) prophylaxis against arrhythmias associated with electrical countershock; (5) termination of ventricular tachycardia; and (6) suppression of repetitive tachycardia associated with Wolff- Parkinson-White (WPW) syndrome. Although quinidine often is successful in producing normal sinus rhythm, its administration in the presence of a rapid atrial rate (flutter and possibly atrial fibrillation) can lead to a further and dangerous increase in the ventricular rate secondary to inhibition of basal vagal tone upon the A-V node. For this reason, digitalis should be used before quinidine when one is attempting to convert atrial flutter or atrial fibrillation to normal sinus rhythm.

Side effects

The most common adverse effects associated with quinidine administration are diarrhea (35%), upper gastrointestinal distress (25%), and light-headedness (15%). Other relatively common adverse effects include fatigue, palpitations, headache (each occurring with an incidence of 7%), anginalike pain, and rash. These adverse effects are generally dose related and reversible with cessation of therapy. In some patients, quinidine administration may bring on thrombocytopenia due to the formation of a plasma protein–quinidine complex that evokes a circulating antibody directed against the blood platelet. Although platelet counts return to normal on cessation of therapy, administration of quinidine or quinine at a later date can cause the reappearance of thrombocytopenia. The cardiac toxicity of quinidine includes A-V and intraventricular block, ventricular tachyarrhythmias, and depression of myocardial contractility. Ventricular arrhythmia induced by quinidine leading to a loss of consciousness has been referred to as quinidine syncope. This devastating side effect is more common in women than in men and may occur at therapeutic or subtherapeutic plasma concentrations. Large doses of quinidine can produce a syndrome known as cinchonism, which is characterized by ringing in the ears, headache, nausea, visual disturbances or blurred vision, disturbed auditory acuity, and vertigo. Larger doses can produce confusion, delirium, hallucinations, or psychoses.Quinidine can decrease blood glucose concentrations, possibly by inducing insulin secretion.

Safety Profile

Poison by ingestion, subcutaneous, intravenous, intramuscular, and intraperitoneal routes. A skin irritant. Implicated in aplastic anemia. When heated to decomposition it emits toxic fumes of NOx.

Drug interactions

Quinidine can increase the plasma concentrations of digoxin, which may in turn lead to signs and symptoms of digitalis toxicity. Gastrointestinal, central nervous system (CNS), or cardiac toxicity associated with elevated digoxin concentrations may occur.Quinidine and digoxin can be administered concurrently; however, a downward adjustment in the digoxin dose may be required. Drugs that have been associated with elevations in quinidine concentrations include acetazolamide, the antacids magnesium hydroxide and calcium carbonate, and the H2-receptor antagonist cimetidine. Cimetidine inhibits the hepatic metabolism of quinidine. Phenytoin, rifampin, and barbiturates increase the hepatic metabolism of quinidine and reduce its plasma concentrations.

Metabolism

Quinidine's bioavailability appears to depend on a combination of metabolism and P-gp efflux. The bioavailabilities of quinidine sulfate and gluconate are 80 to 85% and 70 to 75%, respectively. Once absorbed, quinidine is subject to hepatic first-pass metabolism and is approximately 85% plasma protein bound, with an elimination half-life of approximately 6 hours. Quinidine is metabolized mainly in the liver, and renal excretion of unchanged drug also is significant (~10–50%). The metabolites are hydroxylated derivatives at either the quinoline ring through first-pass O-demethylation or at the quinuclidine ring through oxidation of the vinyl group. These metabolites possess only about one-third the activity of quinidine. Their contribution to overall therapeutic effect of quinidine is unclear. Recently, the clinical significance of the well-documented digoxin–quinidine interaction was described previously under digoxin–drug interactions. Apparently, quinidine (a P-gp substrate) inhibits the renal tubular secretion of digoxin via the P-gp efflux pump, resulting in increased plasma concentration for digoxin.

Purification Methods

Crystallise it from *C6H6 or dry CHCl3/pet ether (b 40-60o), discarding the initial, oily crop of crystals. Dry it under vacuum at 100o over P2O5. It has been used as a chiral catalyst [Wynberg & Staring J Am Chem Soc 104 166 1982, J Org Chem 50 1977 1985]. [Beilstein 23 H 506, 23 I 164, 23 II 414, 23 III/IV 3261, 23/13 V 395.]

Precautions

One of the few absolute contraindications for quinidine is complete A-V block with an A-V pacemaker or idioventricular pacemaker; this may be suppressed by quinidine, leading to cardiac arrest. Persons with congenital QT prolongation may develop torsades de pointes tachyarrhythmia and should not be exposed to quinidine. Owing to the negative inotropic action of quinidine, it is contraindicated in congestive heart failure and hypotension. Digitalis intoxication and hyperkalemia can accentuate the depression of conduction caused by quinidine. Myasthenia gravis can be aggravated severely by quinidine’s actions at the neuromuscular junction. The use of quinidine and quinine should be avoided in patients who previously showed evidence of quinidine- induced thrombocytopenia.

References

Wit, Andrew L. "The Effects of Quinidine on the Cellular Electrophysiology of the Heart: A Brief Review." Journal of Cardiovascular Electrophysiology 3.5(2010):316-322. Alloway, J. A., and M. P. Salata. "Quinidine-induced rheumatic syndromes. " Seminars in Arthritis & Rheumatism 24.5(1995):315-322. Nakano, J, and M. C. R. Jr. "Effect of quinidine on cardiovascular dynamics." Arch Int Pharmacodyn Ther 168.2(1967):400-416.

Check Digit Verification of cas no

The CAS Registry Mumber 56-54-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 6 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 56-54:
(4*5)+(3*6)+(2*5)+(1*4)=52
52 % 10 = 2
So 56-54-2 is a valid CAS Registry Number.
InChI:InChI=1/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/p+1/t13-,14-,19-,20-/m0/s1

56-54-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (Q0006)  Quinidine  >98.0%(T)

  • 56-54-2

  • 5g

  • 170.00CNY

  • Detail
  • TCI America

  • (Q0006)  Quinidine  >98.0%(T)

  • 56-54-2

  • 25g

  • 580.00CNY

  • Detail
  • Alfa Aesar

  • (A12559)  (+)-Quinidine   

  • 56-54-2

  • 1g

  • 114.0CNY

  • Detail
  • Alfa Aesar

  • (A12559)  (+)-Quinidine   

  • 56-54-2

  • 5g

  • 326.0CNY

  • Detail
  • Alfa Aesar

  • (A12559)  (+)-Quinidine   

  • 56-54-2

  • 25g

  • 1250.0CNY

  • Detail

56-54-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name quinidine

1.2 Other means of identification

Product number -
Other names Conchinin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only. Food additives -> Flavoring Agents
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:56-54-2 SDS

56-54-2Synthetic route

(3R,4S)-4-[(2S,3S)-3-(6-Methoxy-quinolin-4-yl)-oxiranylmethyl]-3-vinyl-piperidine-1-carboxylic acid 2-trimethylsilanyl-ethyl ester
865853-19-6

(3R,4S)-4-[(2S,3S)-3-(6-Methoxy-quinolin-4-yl)-oxiranylmethyl]-3-vinyl-piperidine-1-carboxylic acid 2-trimethylsilanyl-ethyl ester

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
With cesium fluoride In N,N-dimethyl-formamide; tert-butyl alcohol at 110℃; for 12h;98%
2-(trimethylsilyl)ethyl 6-methoxy-4-((2R,3R)-3-(((3R,4S)-1-((2-(trimethylsilyl)ethoxy)carbonyl)-3-vinylpiperidin-4-yl)methyl)oxiran-2-yl)quinoline-1(2H)-carboxylate
1207974-84-2

2-(trimethylsilyl)ethyl 6-methoxy-4-((2R,3R)-3-(((3R,4S)-1-((2-(trimethylsilyl)ethoxy)carbonyl)-3-vinylpiperidin-4-yl)methyl)oxiran-2-yl)quinoline-1(2H)-carboxylate

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
Stage #1: 2-(trimethylsilyl)ethyl 6-methoxy-4-((2R,3R)-3-(((3R,4S)-1-((2-(trimethylsilyl)ethoxy)carbonyl)-3-vinylpiperidin-4-yl)methyl)oxiran-2-yl)quinoline-1(2H)-carboxylate With cesium fluoride In N,N-dimethyl-formamide at 180℃; for 0.25h; Microwave irradiation;
Stage #2: With oxygen In N,N-dimethyl-formamide at 20℃; for 19h;
78%
Quinine
130-95-0

Quinine

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
With 9-fluorenone; 2-Heptanol; sodium compound of heptan-2-ol
6'-methoxy-cinchonan-9-one

6'-methoxy-cinchonan-9-one

A

quinidine
56-54-2

quinidine

B

Quinine
130-95-0

Quinine

Conditions
ConditionsYield
With sodium isopropylate; toluene
With 2-pentanol; sodium
sodium ethanolate
141-52-6

sodium ethanolate

6'-methoxy-cinchonan-9-one
569329-55-1

6'-methoxy-cinchonan-9-one

aluminium

aluminium

A

quinidine
56-54-2

quinidine

B

Quinine
130-95-0

Quinine

Conditions
ConditionsYield
quininone;
quininone

quininone

A

quinidine
56-54-2

quinidine

B

Quinine
130-95-0

Quinine

Conditions
ConditionsYield
With ethanol; sodium ethanolate; aluminium
pyridine
110-86-1

pyridine

C59H60FeN7O6

C59H60FeN7O6

A

Fe(protoporphyrin-IX)(pyridine)2(1+)
25875-12-1

Fe(protoporphyrin-IX)(pyridine)2(1+)

B

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
In acetonitrile Equilibrium constant;
C54H55FeN6O6

C54H55FeN6O6

ferriprotoporphyrin IX hydroxide
15489-90-4

ferriprotoporphyrin IX hydroxide

B

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
In acetonitrile Equilibrium constant;
C26H36N2O3Si

C26H36N2O3Si

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: methanesulfonamide; AD-mix-α / water; tert-butyl alcohol / 17 h / 20 °C
2.1: Trimethyl orthoacetate; pyridinium p-toluenesulfonate / dichloromethane / 12 h / 20 °C / Inert atmosphere
2.2: 6 h / 0 - 20 °C / Inert atmosphere
2.3: 0.5 h / 20 °C / Inert atmosphere
3.1: cesium fluoride / N,N-dimethyl-formamide; tert-butyl alcohol / 12 h / 110 °C
View Scheme
(3R,4S)-4-[(2S,3S)-2,3-Dihydroxy-3-(6-methoxy-quinolin-4-yl)-propyl]-3-vinyl-piperidine-1-carboxylic acid 2-trimethylsilanyl-ethyl ester
946491-91-4

(3R,4S)-4-[(2S,3S)-2,3-Dihydroxy-3-(6-methoxy-quinolin-4-yl)-propyl]-3-vinyl-piperidine-1-carboxylic acid 2-trimethylsilanyl-ethyl ester

quinidine
56-54-2

quinidine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: Trimethyl orthoacetate; pyridinium p-toluenesulfonate / dichloromethane / 12 h / 20 °C / Inert atmosphere
1.2: 6 h / 0 - 20 °C / Inert atmosphere
1.3: 0.5 h / 20 °C / Inert atmosphere
2.1: cesium fluoride / N,N-dimethyl-formamide; tert-butyl alcohol / 12 h / 110 °C
View Scheme
benzyl chloride
100-44-7

benzyl chloride

quinidine
56-54-2

quinidine

9-O-benzylquinidine
345217-88-1

9-O-benzylquinidine

Conditions
ConditionsYield
Stage #1: quinidine With sodium hydride In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;
Stage #2: benzyl chloride In N,N-dimethyl-formamide at 20℃; for 20h; Inert atmosphere;
100%
With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; for 0.5h; Inert atmosphere;96%
With sodium hydride In N,N-dimethyl-formamide at 20℃; for 20h;
4-chlorobenzoylmethyl bromide
536-38-9

4-chlorobenzoylmethyl bromide

quinidine
56-54-2

quinidine

C28H30ClN2O3(1+)*Br(1-)

C28H30ClN2O3(1+)*Br(1-)

Conditions
ConditionsYield
In tetrahydrofuran Inert atmosphere;100%
4-(bromoacetyl)toluene
619-41-0

4-(bromoacetyl)toluene

quinidine
56-54-2

quinidine

C29H33N2O3(1+)*Br(1-)

C29H33N2O3(1+)*Br(1-)

Conditions
ConditionsYield
In tetrahydrofuran Inert atmosphere;99%
2-Bromo-4'-methoxyacetophenone
2632-13-5

2-Bromo-4'-methoxyacetophenone

quinidine
56-54-2

quinidine

C29H33N2O4(1+)*Br(1-)

C29H33N2O4(1+)*Br(1-)

Conditions
ConditionsYield
In tetrahydrofuran Inert atmosphere;99%
benzyl bromide
100-39-0

benzyl bromide

quinidine
56-54-2

quinidine

(1S,2R,4S,5R)-1-benzyl-2-((S)-hydroxy(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidin-1-ium bromide
131042-95-0

(1S,2R,4S,5R)-1-benzyl-2-((S)-hydroxy(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidin-1-ium bromide

Conditions
ConditionsYield
In acetone at 60℃; for 4h;98%
α-bromoacetophenone
70-11-1

α-bromoacetophenone

quinidine
56-54-2

quinidine

C28H31N2O3(1+)*Br(1-)

C28H31N2O3(1+)*Br(1-)

Conditions
ConditionsYield
In tetrahydrofuran for 72h;98%
In tetrahydrofuran Inert atmosphere;89%
3,5-bis(trifluoromethyl)benzyl bromide
32247-96-4

3,5-bis(trifluoromethyl)benzyl bromide

quinidine
56-54-2

quinidine

N-[3,5-bis(trifluoromethyl)benzyl]quinidinium bromide
945732-76-3

N-[3,5-bis(trifluoromethyl)benzyl]quinidinium bromide

Conditions
ConditionsYield
In acetone at 60℃; for 4h;97%
In toluene at 80℃; Inert atmosphere;85%
In toluene at 80℃; for 12h;85%
In toluene at 80℃;
In toluene at 80℃;
2-[3,5-bis(4-tert-butylphenyl)phenyl]-4,6-dichloro-5-phenylpyrimidine

2-[3,5-bis(4-tert-butylphenyl)phenyl]-4,6-dichloro-5-phenylpyrimidine

quinidine
56-54-2

quinidine

C76H80N6O4

C76H80N6O4

Conditions
ConditionsYield
With potassium hydroxide In toluene for 2h; Dean-Stark; Reflux;97%
3,5-di-tert-butylbenzyl bromide
62938-08-3

3,5-di-tert-butylbenzyl bromide

quinidine
56-54-2

quinidine

C35H47N2O2(1+)*Br(1-)

C35H47N2O2(1+)*Br(1-)

Conditions
ConditionsYield
In acetone at 60℃; for 4h;97%
4,6-dichloro-2-(2-methoxyphenyl)-5-phenylpyrimidine

4,6-dichloro-2-(2-methoxyphenyl)-5-phenylpyrimidine

quinidine
56-54-2

quinidine

C57H58N6O5

C57H58N6O5

Conditions
ConditionsYield
With potassium hydroxide In toluene for 2h; Dean-Stark; Reflux;96%
2-(bromomethyl)benzonitrile
22115-41-9

2-(bromomethyl)benzonitrile

quinidine
56-54-2

quinidine

C28H30N3O2(1+)*Br(1-)

C28H30N3O2(1+)*Br(1-)

Conditions
ConditionsYield
In acetone at 60℃; for 4h;96%
With sodium iodide In tetrahydrofuran at 20℃; Reflux;
quinidine
56-54-2

quinidine

dihydroquinidine
1435-55-8

dihydroquinidine

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen In methanol under 2280.15 Torr; for 5h;95%
With palladium 10% on activated carbon; hydrogen In methanol under 2280.15 Torr; for 5h;92%
With hydrogenchloride; hydrogen; palladium dichloride
2-methoxybenzyl bromide
52289-93-7

2-methoxybenzyl bromide

quinidine
56-54-2

quinidine

Br(1-)*C28H33N2O3(1+)

Br(1-)*C28H33N2O3(1+)

Conditions
ConditionsYield
In acetone at 60℃; for 4h;95%
With sodium iodide In tetrahydrofuran at 20℃; Reflux;
1-chloro-4-(9-O-dihydroquinidinyl)phthalazine
151955-32-7

1-chloro-4-(9-O-dihydroquinidinyl)phthalazine

quinidine
56-54-2

quinidine

1-(9-O-quinidinyl)-4-(9-O-dihydroquinidinyl)phthalazine
188816-43-5

1-(9-O-quinidinyl)-4-(9-O-dihydroquinidinyl)phthalazine

Conditions
ConditionsYield
With potassium hydroxide; potassium carbonate In toluene for 10h; 32;93%
quinidine
56-54-2

quinidine

4-((S)-hydroxy((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methyl)quinolin-6-ol

4-((S)-hydroxy((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methyl)quinolin-6-ol

Conditions
ConditionsYield
Stage #1: quinidine With boron tribromide In dichloromethane at -78 - 40℃; Inert atmosphere;
Stage #2: With ammonium hydroxide; water In dichloromethane at 0℃;
93%
With sodium thioethylate In N,N-dimethyl-formamide at 110℃; for 6h; Inert atmosphere;79%
With boron tribromide In dichloromethane at -78℃; Inert atmosphere; Reflux;78%
quinidine
56-54-2

quinidine

methyl iodide
74-88-4

methyl iodide

(1S,4S,5R)-2-((S)-methoxy(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine
577782-70-8

(1S,4S,5R)-2-((S)-methoxy(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine

Conditions
ConditionsYield
Stage #1: quinidine With potassium hydride In N,N-dimethyl-formamide; mineral oil; pentane at 0℃; for 1h; Inert atmosphere;
Stage #2: methyl iodide In N,N-dimethyl-formamide; mineral oil; pentane at 0 - 20℃; for 2h; Inert atmosphere;
93%
Stage #1: quinidine With potassium hydride In tetrahydrofuran at 0 - 50℃; for 1h; Inert atmosphere;
Stage #2: methyl iodide In tetrahydrofuran at 0 - 20℃; Inert atmosphere;
86%
Stage #1: quinidine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃;
Stage #2: methyl iodide In N,N-dimethyl-formamide; mineral oil at 20℃;
56%
Stage #1: quinidine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 20℃; for 1h; Schlenk technique; Inert atmosphere;
Stage #2: methyl iodide In N,N-dimethyl-formamide; mineral oil at 20℃; for 16h; Schlenk technique; Inert atmosphere;
41%
Stage #1: quinidine With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 50℃; for 2.5h; Inert atmosphere; Schlenk technique;
Stage #2: methyl iodide In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; for 24h; Inert atmosphere; Schlenk technique;
32%
4,6-dichloro-2-(3,5-diphenylphenyl)-5-phenylpyrimidine

4,6-dichloro-2-(3,5-diphenylphenyl)-5-phenylpyrimidine

quinidine
56-54-2

quinidine

C68H64N6O4

C68H64N6O4

Conditions
ConditionsYield
With potassium hydroxide In toluene for 2h; Dean-Stark; Reflux;92%
3,5-ditrifluoromethylisocyanate
16588-74-2

3,5-ditrifluoromethylisocyanate

quinidine
56-54-2

quinidine

9-O-(3,5-bis(trifluoromethyl)phenylcarbamate)quinidine

9-O-(3,5-bis(trifluoromethyl)phenylcarbamate)quinidine

Conditions
ConditionsYield
In dichloromethane at 0℃; for 2h; Inert atmosphere;92%
3,5-di-tert-butyl-2-hydroxybenzaldehyde
37942-07-7

3,5-di-tert-butyl-2-hydroxybenzaldehyde

quinidine
56-54-2

quinidine

C35H45N3O2

C35H45N3O2

Conditions
ConditionsYield
With magnesium sulfate In ethanol for 5h; Reflux;90%
quinidine
56-54-2

quinidine

(S)-4-((1S,2R,4S,5Z/E)-5-ethylidene-1-azabicyclo[2.2.2]octan-2-yl)hydroxymethyl-6-methoxyquinoline
139237-97-1

(S)-4-((1S,2R,4S,5Z/E)-5-ethylidene-1-azabicyclo[2.2.2]octan-2-yl)hydroxymethyl-6-methoxyquinoline

Conditions
ConditionsYield
Stage #1: quinidine With sulfuric acid In ethanol at 20℃; for 0.166667h;
Stage #2: With rhodium(III) chloride trihydrate In ethanol Reflux;
88%
4-bromomethyltrifluoromethylbenzene
402-49-3

4-bromomethyltrifluoromethylbenzene

quinidine
56-54-2

quinidine

N-(4-trifluoromethylbenzyl)quinidinium bromide

N-(4-trifluoromethylbenzyl)quinidinium bromide

Conditions
ConditionsYield
In toluene at 80℃; Inert atmosphere;87%
In toluene at 80℃; for 12h;87%
In tetrahydrofuran Heating;
allyl bromide
106-95-6

allyl bromide

quinidine
56-54-2

quinidine

C23H28N2O2

C23H28N2O2

Conditions
ConditionsYield
Stage #1: quinidine With sodium hydride In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;
Stage #2: allyl bromide In N,N-dimethyl-formamide at 20℃; for 20h; Inert atmosphere;
87%
chloro-diphenylphosphine
1079-66-9

chloro-diphenylphosphine

quinidine
56-54-2

quinidine

A

(9S)-6'-methoxycinchonan-9-yl diphenylphosphinite

(9S)-6'-methoxycinchonan-9-yl diphenylphosphinite

B

Diphenyl-phosphinic acid (S)-(6-methoxy-quinolin-4-yl)-((1S,2R,4S,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methyl ester

Diphenyl-phosphinic acid (S)-(6-methoxy-quinolin-4-yl)-((1S,2R,4S,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methyl ester

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran at 20℃; for 1.5h;A 86%
B n/a
2-[(tert-butoxycarbonyl)amino]-1-ethanethiol
67385-09-5

2-[(tert-butoxycarbonyl)amino]-1-ethanethiol

quinidine
56-54-2

quinidine

tert‐butyl N‐[2‐({3‐[(1S,3R,4S,6R)‐6‐[(S)‐hydroxy(6‐methoxyquinolin‐4‐yl)methyl]‐1‐azabicyclo[2.2.2]octan‐3‐yl]propyl}sulfanyl)ethyl]carbamate

tert‐butyl N‐[2‐({3‐[(1S,3R,4S,6R)‐6‐[(S)‐hydroxy(6‐methoxyquinolin‐4‐yl)methyl]‐1‐azabicyclo[2.2.2]octan‐3‐yl]propyl}sulfanyl)ethyl]carbamate

Conditions
ConditionsYield
With 2,2-dimethoxy-2-phenylacetophenone In chloroform for 0.166667h; Irradiation;86%
In neat (no solvent) at 80℃; for 60h; Sealed tube; Inert atmosphere;25%
carbon monoxide
201230-82-2

carbon monoxide

quinidine
56-54-2

quinidine

10,11-dihydroquinidine-11-carbaldehyde

10,11-dihydroquinidine-11-carbaldehyde

Conditions
ConditionsYield
With [(2,4-di-t-Bu-C6H3-O)2POCH2]4C; hydrogen; acetylacetonatodicarbonylrhodium(l) In toluene at 90℃; under 15001.5 Torr;85%
(bromomethyl)pentafluorobenzene
1765-40-8

(bromomethyl)pentafluorobenzene

quinidine
56-54-2

quinidine

N-(2,3,4,5,6-pentafluorobenzyl)quinidinium bromide
231303-52-9

N-(2,3,4,5,6-pentafluorobenzyl)quinidinium bromide

Conditions
ConditionsYield
In toluene at 80℃; for 12h;83%
quinidine
56-54-2

quinidine

quinidine 1'-oxide

quinidine 1'-oxide

Conditions
ConditionsYield
Stage #1: quinidine With 3-chloro-benzenecarboperoxoic acid In chloroform at 0 - 20℃; for 3h; pH=10; Inert atmosphere;
Stage #2: With sulphurous acid In acetone at 0 - 20℃; pH=8; Inert atmosphere;
83%
With 3-chloro-benzenecarboperoxoic acid In chloroform at 20℃; for 3.5h; Cooling with ice;83%
Multi-step reaction with 2 steps
1: 3-chloro-benzenecarboperoxoic acid / chloroform / 3 h / 0 - 20 °C
2: sodium hydrogensulfite; hydrogenchloride / water; acetone / 12 h / 0 - 20 °C
View Scheme
p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

quinidine
56-54-2

quinidine

O-tosylquinidine
112661-57-1

O-tosylquinidine

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran for 9h; Heating;82%
With tributyl-amine; potassium hydroxide In dichloromethane; water at 20℃;76%
With sodium hydroxide; benzene
p-(chloromethyl)benzoyl chloride
876-08-4

p-(chloromethyl)benzoyl chloride

quinidine
56-54-2

quinidine

C28H29ClN2O3

C28H29ClN2O3

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran; acetonitrile at 20℃; for 16h;82%

56-54-2Relevant articles and documents

Nickel-Catalyzed Dehydrogenation of N-Heterocycles Using Molecular Oxygen

Banerjee, Debasis,Bera, Atanu,Bera, Sourajit

supporting information, (2020/09/02)

Herein, an efficient and selective nickel-catalyzed dehydrogenation of five- and six-membered N-heterocycles is presented. The transformation occurs in the presence of alkyl, alkoxy, chloro, free hydroxyl and primary amine, internal and terminal olefin, trifluoromethyl, and ester functional groups. Synthesis of an important ligand and the antimalarial drug quinine is demonstrated. Mechanistic studies revealed that the cyclic imine serves as the key intermediate for this stepwise transformation.

Total Asymmetric Synthesis of Quinine, Quinidine, and Analogues via Catalytic Enantioselective Cascade Transformations

Jiang, Yan,Deiana, Luca,Zhang, Kaiheng,Lin, Shuangzheng,Córdova, Armando

supporting information, p. 6016 - 6023 (2019/08/26)

A catalytic asymmetric strategy for the total synthesis of quinuclidine natural products, which includes the completed enantioselective synthesis of the classical targets quinine and quinidine is disclosed. It is based on catalytic asymmetric cascade transformations, which paves the road for the synthesis of both enantiomers of the crucial C4 stereocenter with high enantioselectivity (up to 99 % ee) in one pot. Next, developing a route to all possible stereoisomers of a common early-stage intermediate sets the stage for the total synthesis of different enantiomers or epimers of quinine, quinidine and analogues with high selectivity.

Cellulose type chiral stationary phase based on reduced graphene oxide@silica gel for the enantiomer separation of chiral compounds

Li, Yuanyuan,Li, Qiang,Zhu, Nan,Gao, Zhuxian,Ma, Yulong

, p. 996 - 1004 (2018/07/29)

The graphene oxide (GO) was covalently coupled to the surfaces of silica gel (SiO2) microspheres by amide bond to get the graphene oxide@silica gel (GO@SiO2). Then, the GO@SiO2 was reduced with hydrazine to the reduced graphene oxide@silica gel (rGO@SiO2), and the cellulose derivatives were physically coated on the surfaces of rGO@SiO2 to prepare a chiral stationary phase (CSP) for high performance liquid chromatography. Under the optimum experimental conditions, eight benzene-enriched enantiomers were separated completely, and the resolution of trans-stilbene oxide perfectly reached 4.83. Compared with the blank column of non-bonded rGO, the separation performance is better on the new CSP, which is due to the existence of rGO to produce special retention interaction with analytes, such as π-π stacking, hydrophobic effect, π-π electron-donor–acceptor interaction, and hydrogen bonding. Therefore, the obtained CSP shows special selectivity for benzene-enriched enantiomers, improves separation selectivity and efficiency, and rGO plays a synergistic effect with cellulose derivatives on enantioseparation.

Anti-Selective Asymmetric Nitro-Michael Reaction of Furanones: Diastereocontrol by Catalyst

Sekikawa, Tohru,Kitaguchi, Takayuki,Kitaura, Hayato,Minami, Tatsuya,Hatanaka, Yasuo

supporting information, p. 646 - 649 (2016/03/01)

Catalyst-controlled switching of diastereoselectivity from high syn-selectivity (>98/2 dr, syn) to anti-selectivity (up to 96/4 dr, anti) of the asymmetric nitro-Michael reaction of furanones is described. Anti-diastereoselectivity of the nitro-Michael reaction is very rare. With 0.1-5 mol % loadings of an epi-quinine catalyst, the reaction of 5-substituted 2(3H)-furanones with nitroalkenes smoothly proceeded to give the anti-Michael adducts in good yields (up to 95%) with excellent diastereo- and enantioselectivities (up to 96/4 dr, anti; up to 99% ee). DFT calculations support a model that accounts the high anti-diastereoselectivity. (Chemical Equation Presented).

Syn-selective nitro-Michael addition of furanones to β,β-disubstituted nitroalkenes catalyzed by epi-quinine derivatives

Sekikawa, Tohru,Kitaura, Hayato,Kitaguchi, Takayuki,Minami, Tatsuya,Hatanaka, Yasuo

supporting information, p. 2985 - 2989 (2016/07/06)

Epi-quinine-catalyzed asymmetric nitro-Michael addition of furanones to β,β,-disubstituted nitroalkenes is described. The reaction proceeded smoothly with 1-5 mol % loadings of epi-quinine catalysts at room temperature, giving the corresponding Michael adducts in high yields (72-93%) with extremely high diastereo- and enantioselectivities (>98/2 dr, syn major; 95-99% ee). This reaction provides an effective and straightforward method for constructing all-carbon quaternary stereogenic centers adjacent to oxygen-containing quaternary stereogenic centers.

Alkoxide coordination of iron(III) protoporphyrin IX by antimalarial quinoline methanols: A key interaction observed in the solid-state and solution

Gildenhuys, Johandie,Sammy, Chandre J.,Müller, Ronel,Streltsov, Victor A.,Le Roex, Tanya,Kuter, David,De Villiers, Katherine A.

, p. 16767 - 16777 (2015/10/06)

The quinoline methanol antimalarial drug mefloquine is a structural analogue of the Cinchona alkaloids, quinine and quinidine. We have elucidated the single crystal X-ray diffraction structure of the complexes formed between racemic erythro mefloquine and ferriprotoporphyrin IX (Fe(iii)PPIX) and show that alkoxide coordination is a key interaction in the solid-state. Mass spectrometry confirms the existence of coordination complexes of quinine, quinidine and mefloquine to Fe(iii)PPIX in acetonitrile. The length of the iron(iii)-O bond in the quinine and quinidine complexes as determined by Extended X-ray Absorption Fine Structure (EXAFS) spectroscopy unequivocally confirms that coordination of the quinoline methanol compounds to Fe(iii)PPIX occurs in non-aqueous aprotic solution via their benzylic alkoxide functional group. UV-visible spectrophotometric titrations of the low-spin bis-pyridyl-Fe(iii)PPIX complex with each of the quinoline methanol compounds results in the displacement of a single pyridine molecule and subsequent formation of a six-coordinate pyridine-Fe(iii)PPIX-drug complex. We propose that formation of the drug-Fe(iii)PPIX coordination complexes is favoured in a non-aqueous environment, such as that found in lipid bodies or membranes in the malaria parasite, and that their existence may contribute to the mechanism of haemozoin inhibition or other toxicity effects that lead ultimately to parasite death. In either case, coordination is a key interaction to be considered in the design of novel antimalarial drug candidates.

An easy route to exotic 9-epimers of 9-amino-(9-deoxy) cinchona alkaloids with (8S, 9R) and (8R, 9S)-configurations through two inversions of configuration

Wan, Jing-Wei,Ma, Xue-Bing,He, Rong-Xing,Li, Ming

, p. 557 - 560 (2014/05/06)

Four exotic chiral organocatalysts, 9-amino-(9-deoxy) cinchona alkaloids with (8S, 9R) and (8R, 9S)-configurations, were conveniently synthesized for the first time in 27-72% total yields through two conversions of configuration at the 9-stereogenic centers of commercially available cinchona alkaloids.

Enantioselective α-hydroxylation of β-keto esters catalyzed by cinchona alkaloid derivatives

Wang, Yakun,Li, Zhi,Xiong, Ting,Zhao, Jingnan,Meng, Qingwei

, p. 2155 - 2160 (2014/11/08)

A highly efficient α-hydroxylation of β-keto esters catalyzed by cupreidine in the presence of cumyl hydroperoxide (CHP) was achieved. The reaction was applied to a wide variety of β-keto esters to give products in high yields (up to 95%) with excellent enantioselectivities (up to 97% ee). The reaction had been successfully scaled up to a gram quantity and (S)-5-chloro-2-hydroxy-1-oxo-2,3-dihydro-1H-indene-2-carboxylate - the important intermediate of Indoxacarb were obtained in 96% yield with 86% ee. The enantiomeric excess could be improved to 99% by crystallization, and this method has prospect of industrial application for its advantages of enantioselectivity, ease of catalyst preparation and reclamation of catalyst. Georg Thieme Verlag Stuttgart. New York.

Relative to quinine and quinidine, their 9-epimers exhibit decreased cytostatic activity and altered heme binding but similar cytocidal activity versus Plasmodium falciparum

Gorka, Alexander P.,Sherlach, Katy S.,De Dios, Angel C.,Roepea, Paul D.

, p. 365 - 374 (2013/03/28)

The 9-epimers of quinine (QN) and quinidine (QD) are known to exhibit poor cytostatic potency against P. falciparum (Karle JM, Karle IL, Gerena L, Milhous WK, Antimicrob. Agents Chemother. 36:1538-1544, 1992). We synthesized 9-epi-QN (eQN) and 9-epi-QD (eQD) via Mitsunobu esterification-saponification and evaluated both cytostatic and cytocidal antimalarial activities. Relative to the cytostatic activity of QN and QD, we observed a large decrease in cytostatic activity (higher 50% inhibitory concentration [IC50s]) against QN-sensitive strain HB3, QN-resistant strain Dd2, and QN-hypersensitive strain K76I, consistent with previous work. However, we observed relatively small changes in cytocidal activity (the 50% lethal dose), similar to observations with chloroquine (CQ) analogues with a wide range of IC50s (see the accompanying paper [A. P. Gorka, J. N. Alumasa, K. S. Sherlach, L. M. Jacobs, K. B. Nickley, J. P. Brower, A. C. de Dios, and P. D. Roepe, Antimicrob. Agents Chemother. 57:356-364, 2013]). Compared to QN and QD, the 9-epimers had significantly reduced hemozoin inhibition efficiency and did not affect pH-dependent aggregation of ferriprotoporphyrin IX (FPIX) heme. Magnetic susceptibility measurements showed that the 9-epimers perturb FPIX monomer-dimer equilibrium in favor of monomer, and UV-visible (VIS) titrations showed that eQN and eQD bind monomer with similar affinity relative to QN and QD. However, unique ring proton shifts in the presence of zinc(II) protoporphyrin IX (ZnPIX) indicate that binding of the 9-epimers to monomeric heme is via a distinct geometry. We isolated eQN- and eQD-FPIX complexes formed under aqueous conditions and analyzed them by mass, fluorescence, and UVVIS spectroscopies. The 9-epimers produced low-fluorescent adducts with a 2:1 stoichiometry (drug to FPIX) which did not survive electrospray ionization, in contrast to QN and QD complexes. The data offer important insight into the relevance of heme interactions as a drug target for cytostatic versus cytocidal dosages of quinoline antimalarial drugs and further elucidate a surprising structural diversity of quinoline antimalarial drug-heme complexes. Copyright

Chiral benzisoselenazolones: Conformational analysis based on experimental and DFT calculated 77Se NMR

Zielińska-B?ajet, Mariola,Boratyński, Przemys?aw J.,Palus, Jerzy,Skarzewski, Jacek

, p. 10223 - 10229 (2013/11/19)

A series of new enantiomeric N-substituted benzisoselenazol-3(2H)-ones were prepared from 2-(chloroseleno)benzoyl chloride and 9-amino-deoxyquinine (both 9-native and 9-epi) as well as the other chiral primary amines. The 77Se NMR parameters for the obtained benzisoselenazolones were measured and theoretically calculated at the DFT level of theory using B97-2 hybrid functional and cc-pVTZ basis set. The DFT 77Se chemical shifts for the lowest energy conformers were in agreement with the experimental data, while the conformers of higher energy showed markedly worse fit. Interestingly, the preferred conformation for 2-(1-arylalkyl)-benzisoselenazolones is the gauche type (Se-N-C-H≈±180), and it is in agreement with those observed in crystals (X-ray). The calculation predicts a much higher sensitivity for the 77Se chemical shift of the conformation than for the corresponding 13C data. In the 77Se NMR spectra of chiral benzisoselenazolones with added racemic or l-N-Boc-phenylglycine, chiral discrimination could not be observed mostly due to signal broadening. In the 1H NMR spectra, the benzisoselenazole derived from epi-9-amino-deoxyquinine induced splittings of the amino acid signals, thus allowing for discrimination of the enantiomers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 56-54-2